Want to join the conversation?
Nomura Securities analyst Romit Shah probes $MU if expenses are expected to remain elevated through the course of the year while ramping new products. CFO Ernie Maddock says that expenses will occur as there is a concentration of new products, but it might not occur each quarter. In 4Q16, they will be particularly high relative to recent history.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?